New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC
Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.
